LX201
- Generic Name
- LX201
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- 10EHY3D8GY
- Background
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.
- Indication
Investigated for use/treatment in eye disorders/infections and transplant (rejection).
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
- Conditions
- Corneal TransplantationCorneal Graft Rejection
- Interventions
- Other: Placebo
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00447642
- Locations
- ๐บ๐ธ
Wilmer Eye Institute, Cornea Service, Baltimore, Maryland, United States
๐บ๐ธBascom Palmer Eye Institute, Miami, Florida, United States
๐บ๐ธDuke University Eye Center, Durham, North Carolina, United States
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Lux Biosciences, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT00447187
- Locations
- ๐บ๐ธ
USC Doheny Eye Institute, Los Angeles, California, United States
๐บ๐ธUniversity of Illinois at Chicago, Chicago, Illinois, United States
๐บ๐ธThe Eye Center at Union Memorial Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.